JP2006504793A5 - - Google Patents

Download PDF

Info

Publication number
JP2006504793A5
JP2006504793A5 JP2004571986A JP2004571986A JP2006504793A5 JP 2006504793 A5 JP2006504793 A5 JP 2006504793A5 JP 2004571986 A JP2004571986 A JP 2004571986A JP 2004571986 A JP2004571986 A JP 2004571986A JP 2006504793 A5 JP2006504793 A5 JP 2006504793A5
Authority
JP
Japan
Prior art keywords
propyl
hydroxy
acetamide
difluoro
benzyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004571986A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006504793A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/028503 external-priority patent/WO2004024081A2/en
Publication of JP2006504793A publication Critical patent/JP2006504793A/ja
Publication of JP2006504793A5 publication Critical patent/JP2006504793A5/ja
Pending legal-status Critical Current

Links

JP2004571986A 2002-09-10 2003-09-10 アセチル2−ヒドロオキシ−1,3−ダイアミノアルカン Pending JP2006504793A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US40945302P 2002-09-10 2002-09-10
US45223103P 2003-03-05 2003-03-05
US49175703P 2003-08-01 2003-08-01
PCT/US2003/028503 WO2004024081A2 (en) 2002-09-10 2003-09-10 Acetyl 2-hydroxy-1,3 diaminoalkanes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010273586A Division JP2011084568A (ja) 2002-09-10 2010-12-08 アセチル2−ヒドロオキシ−1,3−ダイアミノアルカン

Publications (2)

Publication Number Publication Date
JP2006504793A JP2006504793A (ja) 2006-02-09
JP2006504793A5 true JP2006504793A5 (https=) 2011-02-10

Family

ID=31999211

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004571986A Pending JP2006504793A (ja) 2002-09-10 2003-09-10 アセチル2−ヒドロオキシ−1,3−ダイアミノアルカン
JP2010273586A Pending JP2011084568A (ja) 2002-09-10 2010-12-08 アセチル2−ヒドロオキシ−1,3−ダイアミノアルカン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010273586A Pending JP2011084568A (ja) 2002-09-10 2010-12-08 アセチル2−ヒドロオキシ−1,3−ダイアミノアルカン

Country Status (23)

Country Link
US (3) US7244725B2 (https=)
EP (1) EP1565443A4 (https=)
JP (2) JP2006504793A (https=)
KR (1) KR20060057520A (https=)
AR (1) AR043679A1 (https=)
AU (1) AU2003267132A1 (https=)
BR (1) BR0314188A (https=)
CA (1) CA2498248A1 (https=)
EA (1) EA009196B1 (https=)
EC (1) ECSP055696A (https=)
GE (1) GEP20074166B (https=)
IS (1) IS7732A (https=)
MA (1) MA27472A1 (https=)
MX (1) MXPA05002695A (https=)
NO (1) NO20051239L (https=)
NZ (1) NZ539095A (https=)
OA (1) OA12919A (https=)
PE (1) PE20041079A1 (https=)
PL (1) PL376511A1 (https=)
TW (1) TWI336320B (https=)
UA (1) UA84407C2 (https=)
UY (1) UY27967A1 (https=)
WO (1) WO2004024081A2 (https=)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7351738B2 (en) * 2002-11-27 2008-04-01 Elan Pharmaceuticals, Inc. Substituted ureas and carbamates
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
JP2006524258A (ja) * 2003-04-21 2006-10-26 イーラン ファーマスーティカルズ、インコーポレイテッド フェナシル2−ヒドロキシ−3−ジアミノアルカン
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
JP2007522129A (ja) * 2004-01-21 2007-08-09 エラン ファーマシューティカルズ,インコーポレイテッド アスパラギン酸プロテアーゼ阻害薬を用いるアミロイドーシスの処置方法
CA2558036A1 (en) * 2004-03-09 2005-09-22 Elan Pharmaceuticals, Inc. Substituted hydroxyethylamine aspartyl protease inhibitors
JP2007528404A (ja) * 2004-03-09 2007-10-11 エラン ファーマシューティカルズ,インコーポレイテッド 置換された尿素およびカルバメート、フェナシル−2−ヒドロキシ−3−ジアミノアルカン、ならびにベンズアミド−2−ヒドロキシ−3−ジアミノアルカン系のアスパラギン酸プロテアーゼ阻害薬
US20050239836A1 (en) 2004-03-09 2005-10-27 Varghese John Substituted hydroxyethylamine aspartyl protease inhibitors
CA2556826A1 (en) * 2004-03-09 2005-09-22 Elan Pharmaceuticals, Inc. Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors
US7585885B2 (en) 2004-04-22 2009-09-08 Eli Lilly And Company Pyrrolidine derivatives useful as BACE inhibitors
WO2005108358A2 (en) 2004-04-22 2005-11-17 Eli Lilly And Company Pyrrolidine derivatives useful as bace inhibitors
EP1773756A2 (en) 2004-07-09 2007-04-18 Elan Pharmaceuticals, Inc. Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors
EP1773758A1 (en) * 2004-07-09 2007-04-18 Elan Pharmaceuticals, Inc. Oxime derivative hydroxyethylamine aspartyl-protease inhibitors
TW200624426A (en) 2004-09-21 2006-07-16 Lilly Co Eli BACE inhibitors
CA2597574A1 (en) * 2005-02-14 2006-08-17 Pfizer Products Inc. Substituted hydroxyethylamines
ES2400287T3 (es) * 2005-03-14 2013-04-08 High Point Pharmaceuticals, Llc Derivados de benzazol, composiciones y procedimientos de uso como inhibidores de beta-secretasa
KR20080015079A (ko) 2005-04-08 2008-02-18 코멘티스, 인코포레이티드 베타 세크레타제 활성을 억제하는 화합물 및 이것의 사용방법
WO2007047305A1 (en) * 2005-10-12 2007-04-26 Elan Pharmaceuticals, Inc. Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors
WO2007047306A1 (en) * 2005-10-12 2007-04-26 Elan Pharmaceuticals, Inc. Methods of treating amyloidosis using aryl-cyclopropyl derivative aspartyl protease inhibitors
WO2007061670A1 (en) 2005-11-21 2007-05-31 Amgen Inc. Beta-secretase modulators and methods of use
US7872009B2 (en) 2005-11-21 2011-01-18 Amgen Inc. Beta-Secretase modulators and methods of use
US7745484B2 (en) 2005-11-21 2010-06-29 Amgen Inc. Beta-secretase modulators and methods of use
US7838676B2 (en) 2005-11-21 2010-11-23 Amgen Inc. Beta-secretase modulators and methods of use
CA2630459A1 (en) * 2005-11-22 2007-05-31 Pfizer Products Inc. Substituted azacycloalkanes useful for treating cns conditions
AU2007324490A1 (en) * 2006-11-23 2008-05-29 Novartis Ag 2-hydroxy-1,3-diaminopropane derivatives
CA2687608C (en) 2007-05-25 2013-07-02 Amgen Inc. Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use
US8163909B2 (en) 2007-05-25 2012-04-24 Amgen Inc. Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use
US7803809B2 (en) 2008-11-12 2010-09-28 Amgen Inc. Substituted pyrano [2,3-b] pyridinamine compounds as beta-secretase modulators and methods of use
DE102008039083A1 (de) 2008-08-21 2010-02-25 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Aminopyrazole und ihre Verwendung
CA2736130C (en) * 2008-09-11 2014-01-14 Amgen Inc. Spiro-tetracyclic ring compounds as beta-secretase modulators and methods of use
EP2504330A1 (en) 2009-11-23 2012-10-03 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
US9296698B2 (en) 2009-11-23 2016-03-29 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
AU2011207679B2 (en) 2010-01-19 2013-10-10 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
EP2547685A1 (en) 2010-03-15 2013-01-23 Amgen Inc. Spiro-tetracyclic ring compounds as beta - secretase modulators
MX2012010657A (es) 2010-03-15 2013-02-07 Amgen Inc Compuestos de espiro amino-dihidrooxazina y amino-dihidrotiazina como moduladores de beta-secretasa y su uso medico.
EP2673279A1 (en) 2011-02-07 2013-12-18 Amgen Inc. 5-amino-oxazepine and 5-amino-thiazepane compounds as beta-secretase antagonists and methods of use
WO2013044092A1 (en) 2011-09-21 2013-03-28 Amgen Inc. Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
WO2014078314A1 (en) 2012-11-15 2014-05-22 Amgen Inc. Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
CA3032141A1 (en) 2016-07-29 2018-02-01 Vadim ALEXANDROV Compounds and compositions and uses thereof
BR112020001433A2 (pt) 2017-08-02 2020-07-28 Sunovion Pharmaceuticals Inc. compostos de isocromano e usos dos mesmos
WO2019168874A1 (en) 2018-02-27 2019-09-06 The Research Foundation For The State University Of New York Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same
PL243516B1 (pl) * 2020-05-20 2023-09-04 Univ Jagiellonski Nowe pochodne 9H-fluorenu lub ich farmaceutycznie dopuszczalne sole
CN113189089B (zh) * 2021-03-19 2022-05-17 四川轻化工大学 一种臭氧检测试剂及其制备装置和制备方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61118352A (ja) * 1984-10-29 1986-06-05 イー・アール・スクイブ・アンド・サンズ・インコーポレイテツド アミノ酸エステルおよびアミドレニン抑制剤
US5552558A (en) * 1989-05-23 1996-09-03 Abbott Laboratories Retroviral protease inhibiting compounds
US5362912A (en) * 1989-05-23 1994-11-08 Abbott Laboratories Process for the preparation of a substituted diaminodiol
US5387742A (en) * 1990-06-15 1995-02-07 Scios Nova Inc. Transgenic mice displaying the amyloid-forming pathology of alzheimer's disease
WO1992013069A1 (en) * 1991-01-21 1992-08-06 Imperial College Of Science, Technology & Medicine Test and model for alzheimer's disease
FR2676173B1 (fr) * 1991-05-06 1993-08-13 Oreal Composition cosmetique contenant un agent alcalinisant sans odeur.
EP0620849B1 (en) * 1992-01-07 2003-06-25 Elan Pharmaceuticals, Inc. Transgenic animal models for alzheimer's disease
DE4208756A1 (de) * 1992-03-19 1993-09-23 Basf Ag Diaminoalkane, verfahren zu deren herstellung sowie kraftstoffe und schmierstoffe, enthaltend die diaminoalkane
US5604102A (en) * 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
US5766846A (en) * 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
US5968942A (en) * 1992-08-25 1999-10-19 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
EP1302468B1 (en) * 1992-12-29 2008-12-17 Abbott Laboratories Processes and intermediates for manufacturing retroviral protease inhibiting compounds
AU702293B2 (en) * 1993-10-27 1999-02-18 Athena Neurosciences, Inc. Transgenic animals harboring APP allele having Swedish mutation
US5877399A (en) * 1994-01-27 1999-03-02 Johns Hopkins University Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
FI974437A7 (fi) * 1995-06-06 1997-12-05 Pfizer Substituoituja N-(indoli-2-karbonyyli)amideja ja johdannaisia glykogee nifosforylaasi-inhibiittoreina
EP0970041A1 (de) * 1996-07-03 2000-01-12 Hans Schwarzkopf GmbH & Co. KG Neue diaminoalkane und oxidationsfärbemittel
CA2280096A1 (en) * 1997-02-04 1998-08-06 The Regents Of The University Of California Nanomolar, non-peptide inhibitors of cathepsin d
AU8673598A (en) * 1997-08-01 1999-02-22 University Of Florida Neuraminidase inhibitors
CN1300320C (zh) 1998-09-24 2007-02-14 法玛西雅厄普约翰美国公司 阿尔茨海默氏疾病分泌酶
US6846813B2 (en) * 2000-06-30 2005-01-25 Pharmacia & Upjohn Company Compounds to treat alzheimer's disease
EP1299352B1 (en) * 2000-06-30 2005-12-28 Elan Pharmaceuticals, Inc. Compounds to treat alzheimer's disease
PE20020276A1 (es) * 2000-06-30 2002-04-06 Elan Pharm Inc COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
BR0210122A (pt) * 2001-06-01 2004-06-15 Elan Pharm Inc Composto ou um sal farmaceuticamente aceitável do mesmo, método para o tratamento ou prevenção de uma doença, uso do composto ou de seu sal, e, método para preparar o mesmo
WO2003006423A1 (en) * 2001-07-11 2003-01-23 Elan Pharmaceuticals, Inc. N-(3-amino-2-hydroxy-propyl) substituted alkylamide compounds
NZ533107A (en) * 2001-11-08 2007-04-27 Upjohn Co N, N'-substituted-1,3-diamino-2-hydroxypropane derivatives
BR0214736A (pt) * 2001-12-06 2004-11-23 Elan Pharm Inc Composto e seus sais farmaceuticamente aceitáveis, composição farmacêutica e método de tratar seres humanos ou animais que sofrem de doenças ou condições
CN1732161A (zh) * 2002-09-06 2006-02-08 艾伦药物公司 1,3-二氨基-2-羟基丙烷前体药物衍生物

Similar Documents

Publication Publication Date Title
JP2006504793A5 (https=)
EP1112251B1 (fr) Derives d'azetidine, leur preparation et les medicaments les contenant
CN1046274C (zh) 用作消炎剂的异噁唑啉化合物
CN1028103C (zh) 哌啶基苯并咪唑类化合物的制备方法
US5554633A (en) Substituted amines as tachykinin receptor antagonists
CN1173948C (zh) α-取代的芳基磺酰氨基异羟肟酸和制备方法及其组合物
SK283860B6 (sk) Sírne deriváty azetidínových zlúčenín, spôsob ich prípravy, farmaceutický prostriedok s ich obsahom a ich použitie
CZ4994A3 (en) Pyrrolidine derivatives, process of their preparation and medicaments in which said derivatives are comprised
WO2001064633A1 (fr) Compositions pharmaceutiques contenant des derives de 3-amino-azetidine, les nouveaux derives et leur preparation
CN1882587A (zh) 三环化合物作为甘氨酸转运抑制剂的用途
JPH03206086A (ja) 芳香族アミン化合物、その製造方法、およびそれを含む医薬
LU84070A1 (fr) Derives phenylcyclobutyliques,leur procede de preparation et leur application therapeutique
WO1994007843A1 (en) Cyclohexyl amine derivatives and their use as tachykinin antagonists
ZA200607542B (en) MTP inhibiting aryl piperidines or piperazines substituted with 5-membered heterocycles
CA2436526A1 (en) Heterocyclic sulfonamide inhibitors of beta amyloid production
EP1680402A1 (fr) Derives de n-[[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
JP2008512470A5 (https=)
TW201712004A (zh) 吡唑衍生物或其藥理學上容許之鹽
JP2010506910A5 (https=)
JPH08291112A (ja) アリールアルキル−アミンおよびアミド
JP2007508395A5 (https=)
JP2008520642A5 (https=)
JP2001515509A (ja) 新規キノリン−およびナフタレンカルボキサミド、医薬組成物およびカルパインの阻害方法
JP2005513036A (ja) キノリン誘導体、それらの製造方法、ならびにs−CD23により媒介される障害の治療におけるそれらの使用
CN1052112A (zh) 萘基唑烷酮衍生物